Board summary
Key figures
48,732
Registered population
72.8% aged 18–64
10.7%
Aged 65+
ICB 14.9% · England 17.9%
38.7%
Ethnic minority (non-White)
21.5% Asian · England 9.6%
31.1%
In IMD quintile 1
ICB 40.7% · England 21.0%
~13,364
Core20 residents (est.)
Resident basis; registered basis ~14,192 · see page 3
4,897
Hypertension register
+5.63% in 3 yrs · England +5.60%
653
SMI register
6.9% of Manchester (LAD)'s
1,000
COPD register
Reviews +2.42% in 3 yrs
Forecast to 2030
5,619
Hypertension patients, 2030
+722 on today
73.5%
QRISK ≥20% on statins, 2030
+4.72pp over 3 yrs
2.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Cervical screening in women 25-49 trails England.
Coverage is 55.5% against 66.8% in England and 57.2% in Manchester (LAD), which may reflect unverified recall or access barriers.
Under-80 BP control three-year change lags England.
Control is 69.7% (England 67.8%), but three-year change was -0.2% against +3.2% in England, which may indicate follow-up gaps.
Asthma review rate exceeds England and borough.
Annual reviews reached 75.1% (England 65.7%) and grew +8.9% over three years, though about 750 of 2,999 register patients remain unreviewed.
Population, age and ethnicity
Working-age adults make up 72.8% of registered patients alongside 38.7% ethnic minority residents
Across 48,732 registered patients, 72.8% are aged 18–64 (Manchester (LAD) 68.9%, NHS Greater Manchester ICB 63.3%, England 62.7%), while 10.7% are aged 65+ (Manchester (LAD) 9.6%, ICB 14.9%, England 17.9%) and 16.5% are aged 0–17 (Manchester (LAD) 21.4%, ICB 21.8%, England 19.6%). For ethnicity, based on Census usual residents rather than registered patients, 61.3% are White (Manchester (LAD) 56.8%, ICB 76.4%, England 81.1%) and 38.7% ethnic minority, including 21.5% Asian or Asian British (Manchester (LAD) 20.9%, ICB 13.6%, England 9.6%).
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Manchester LA) | 2,357 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.2% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Manchester LA) | 1,281 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Manchester LA) | 26.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share is 31.1% overall, spanning 51.1 percentage points across member practices
Core20 patients (living in the most deprived 20% of national areas) comprise 31.1% of registered patients, below Manchester (LAD) (59.8%) and NHS Greater Manchester ICB (40.7%), but above England (21.0%). A 2.00 percentage point discrepancy exists against the 29.1% weighted practice share. Deprivation spans 51.1 pp across practices: Ladybarn Group Practice records 51.1% (an estimated 6,202 patients), The Borchardt Medical Centre records 45.9% (an estimated 4,475 patients), and Fallowfield Medical Centre records 0.0%. Outreach should be weighted toward Ladybarn Group Practice and The Borchardt Medical Centre.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
653
SMI register
1.24% recorded prevalence
301
Learning disability register
0.57% recorded prevalence
10
Care homes, 265 beds
In the PCN catchment
8.7%
Provide unpaid care
Manchester (LAD), Census 2021
The PCN records 653 patients on the severe mental illness register (prevalence 1.2% versus Manchester (LAD) 1.3%, NHS Greater Manchester ICB 1.1%, England 1.0%) and 301 on the learning disability register (0.6% versus Manchester (LAD) 0.7%, ICB 0.6%, England 0.6%). Catchment data identify 10 care homes with 265 beds.
Severe mental illness: physical health checks
Across 653 patients on the severe mental illness register, 81.4% received a blood pressure check (England 83.4%) and 81.4% had BMI recorded (England 82.1%). Incomplete monitoring may leave cardiovascular risk unreviewed, which record audits could test.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,897
Hypertension register
+5.63%
Register growth, 3 yrs
Manchester (LAD) +4.49% · England +5.60%
−0.15pp
BP control, under 80
≤140/90 · −0.18pp aged 80+
+722
More patients by 2030
Forecast 5,619 (10.36%)
Hypertension case-finding and control
Recorded hypertension prevalence is 9.3% (4,897 patients), below Manchester (LAD) at 10.5%, NHS Greater Manchester Integrated Care Board at 14.4% and England at 15.2%, though crude rates are unadjusted for age structure and observation periods are unconfirmed. Recent blood pressure checks reach 91.5% (England 90.0%) and under-80 control is 69.7% (England 67.8%). Yet three-year control has stalled: under-80 blood pressure control changed by -0.2% from 2023 to 2025, trailing England (+3.2%). Stalling three-year blood pressure control despite good snapshot attainment may indicate that routine reviews miss active titration, which recall audits could test.
Lipids and statins
While 81.2% of diabetes patients without CVD receive statins (England 73.2%), only 62.8% of patients with QRISK ≥ 20% receive lipid-lowering therapy, below Manchester (LAD) at 70.5% and England at 63.6%. Lower therapy uptake in high-risk patients may reflect primary prevention review gaps, which clinical audits could test.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 73,428 | £2.10 | £1.94 | £1.86 | £154,199 |
| Cardiovascular (all), 2025 | 99,659 | £2.41 | £3.15 | £3.33 | £240,178 |
In 2026, 73,428 lipid-regulating drug items were prescribed at £2.10 per item, below Manchester (LAD) at £2.21 but above England (£1.86), spending £17,623 more than at England's unit cost across those items. Higher unit costs than England could reflect formulation selection across practices, which prescribing audits could test.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+8.92%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.92%
Asthma prevalence, PCN 3-yr % change
The PCN records 2,999 asthma patients (prevalence 5.9%, England 6.6%) and 1,000 COPD patients (1.9%, England 1.9%). While annual asthma reviews reached 75.1% (England 65.7%, Manchester (LAD) 67.0%) after rising +8.9% from 2023 to 2025 (England +4.4%), about 750 registered asthma patients lack a recorded review. Asthma prescribing is 1,630 items per 1,000 population aged 5-19 (England 1,488), and COPD reviews stand at 77.3% (England 76.4%). Prioritising outstanding reviews could close unmonitored risk across vulnerable respiratory patients.
Cancer register and children's immunisation
Cancer register prevalence is 2.2% across 1,166 patients (England 3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 coverage at 12 months was 83.2% (England 91.0%) and MMR1 at 24 months was 83.6% (England 88.3%), below the 95.0% target. At age 5, MMR dose 1 reached 95.1% whereas dose 2 was 87.8%, a 7.3 pp difference that may reflect recall barriers, which call-recall audits could test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2, above England (55.3%) but 19.4 pp below the 75.0% national ambition by 2028. This leaves a gap of about 2,270 extra early diagnoses across the ICB, where known-stage coverage was 70.8% (11,679 of 16,492). For the PCN, cervical screening coverage in women aged 25-49 is 55.5%, below Manchester (LAD) (57.2%), NHS Greater Manchester Integrated Care Board (65.9%), and England (66.8%). Practice coverage includes Bodey Medical Centre at 48.5% and Mauldeth Medical Centre at 44.1%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Manchester University NHS Foundation Trust achieved 72.8% against the 85.0% cancer 62-day referral to treatment standard, trailing Northern Care Alliance NHS Foundation Trust (78.6%), Stockport NHS Foundation Trust (74.7%) and NHS Greater Manchester Integrated Care Board (75.7%), but above England (71.2%). The trust met the 28-day faster diagnosis standard at 80.1% (75.0% standard; England 79.3%). In July 2026 diagnostics, 11.7% waited 6+ weeks for MRI and 14.7% for CT at Manchester University NHS Foundation Trust, above Northern Care Alliance (5.1% and 4.1%) and Stockport (1.4% and 2.9%). These figures reflect provider activity rather than PCN delivery.
| Pathways within standard (%) | Manchester | Stockport | Northern Care Alliance | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 83.21 | 75.20 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 97.39 | 94.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 74.67 | 78.65 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Stockport | Northern Care Alliance | England |
|---|---|---|---|---|
| MRI | 11.68 | 1.41 | 5.09 | 21.40 |
| CT | 14.66 | 2.93 | 4.10 | 9.92 |
| Echocardiography | 4.91 | 17.46 | 31.48 | 28.48 |
| Colonoscopy | 4.51 | 5.53 | 40.04 | 30.83 |
| Gastroscopy | 29.35 | 5.31 | 36.48 | 29.02 |
| All 15 DM01 tests | 8.98 | 14.08 | 15.71 | 23.14 |
| Community services activity | Manchester residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 96,995 | 573,310 |
| Referrals | 20,270 | 94,470 |
| Patients with a contact | 31,040 | 183,535 |
Community services (residents of Manchester), Jun 2026 (provisional). In June 2026 (provisional), community health services recorded 96,995 contacts for Manchester borough residents, with 42,015 (43.3%) involving adults aged 65 and over. These figures describe borough resident contacts across community providers rather than PCN-level activity, reflecting broader local system contacts for older residents.
Practice variation and patient experience
Practice vaccination achievement spans 67.0 pp alongside a 43.2 pp phone access spread
In 2025/26, clinical QOF achievement reached 93.3% at Mauldeth Medical Centre and up to 100.0% at Fallowfield Medical Centre (England 97.1%). In contrast, vaccination and immunisation achievement spans 67.0 pp across practices, from 15.6% at Mauldeth Medical Centre to 82.7% at Withington Medical Practice (England 55.2%), showing wide practice variation across the network.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Bodey | 95 | 15.4 | 72.3% | 70.2% | 91.8% |
| Borchardt | 96 | 45.9 | 59.1% | 83.6% | 89.0% |
| Withington | 72 | 17.3 | 91.3% | 78.2% | 87.8% |
| Fallowfield | 77 | 0.0 | 92.3% | 72.1% | 84.5% |
| Ladybarn | 113 | 51.1 | 49.1% | 70.0% | 82.6% |
| Mauldeth | 113 | 6.5 | 82.3% | 67.0% | 81.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Ten of 25 measures trail England's three-year change, led by heart failure reviews
Across 25 compared measures, 10 trail England's 3-year change. The widest lags are heart failure reviews (+1.2% vs +8.7% in England), under-80 blood pressure control (-0.2% vs +3.2%), and psychosis alcohol recording (+2.7 pp vs +5.4 pp). Conversely, the PCN outpaced national trends in severe mental illness blood pressure checks (+9.7 pp vs +4.4 pp) and recorded dementia prevalence (+23.2% vs +6.0%). Slower review and management growth may reflect recall follow-up gaps, which clinical audits could test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Depression register
BP control, under 80
Alcohol record (psychosis)
Hypertension treated to target
Breast screening (53-70)
BP check (SMI)
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Manchester (LAD) | Asset | PCN | Manchester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 10 (265 beds) | n/a | Schools (catchment) | 52 | n/a |
| Children's centres | 3 | 34 | Places of worship | 33 | 289 |
| Libraries | 3 | 16 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 6 | 68 | Primary academies | 6 | 50 |
| Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
About 750 of 2,999 registered asthma patients lack a recorded review in the last 12 months (75.1% reviewed, above Manchester (LAD) at 67.0% and England at 65.7%). Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school MMR2 and booster recall
In Q1 2025/26, age-5 MMR2 is 87.8% versus 95.1% for MMR1 in the same 82-child cohort (7.3 pp lower), and the 4-in-1 booster is 82.9%, below the 95.0% target by 12.1 pp. For discussion, practices could audit age-5 cohorts missing MMR2 or the 4-in-1 booster and offer flexible family appointments. Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Cervical screening non-responder recall
Cervical screening coverage in women aged 25-49 is 55.5%, below Manchester (LAD) at 57.2% by 1.7 pp, NHS Greater Manchester ICB at 65.9% by 10.4 pp, and England at 66.8% by 11.3 pp. Moderate effort to run.
Evidence base: uptake is the delivery measure of the national cancer screening programme; distance to the acceptable and achievable standards is the outreach target.
Policy anchor: Shift 3: sickness to prevention; Eliminate cervical cancer by 2040.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally adapted cardiovascular outreach (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Weighted Core20 outreach allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool MMR booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school MMR2 and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Cervical screening non-responder recall (p12) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
